Literature DB >> 24587637

Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis.

Jian-Bo Zhao1, Chao Feng1, Qiao-Hua Zhu1, Xiao-Feng He1, Yan-Hao Li1, Yong Chen1.   

Abstract

AIM: To evaluate transjugular intrahepatic portosystemic shunt (TIPS) with covered stents for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (PVTT).
METHODS: Eleven advanced HCC patients (all male, aged 37-78 years, mean: 54.3 ± 12.7 years) presented with acute massive upper gastrointestinal bleeding (n = 9) or refractory ascites (n = 2) due to tumor thrombus in the main portal vein. The diagnosis of PVTT was based on contrast-enhanced computed tomography and color Doppler sonography. The patients underwent TIPS with covered stents. Clinical characteristics and average survival time of 11 patients were analyzed. Portal vein pressure was assessed before and after TIPS. The follow-up period was 2-18 mo.
RESULTS: TIPS with covered stents was successfully completed in all 11 patients. The mean portal vein pressure was reduced from 32.0 to 11.8 mmHg (t = 10.756, P = 0.000). Gastrointestinal bleeding was stopped in nine patients. Refractory ascites completely disappeared in one patient and was alleviated in another. Hepatic encephalopathy was observed in six patients and was resolved with drug therapy. During the follow-up, ultrasound indicated the patency of the shunt and there was no recurrence of symptoms. Death occurred 2-14 mo (mean: 5.67 mo) after TIPS in nine cases, which were all due to multiple organ failure. In the remaining two cases, the patients were still alive at the 16- and 18-mo follow-up, respectively.
CONCLUSION: TIPS with covered stents for HCC patients with tumor thrombus in the main portal vein is technically feasible, and short-term efficacy is favorable.

Entities:  

Keywords:  Covered stent; Hepatocellular carcinoma; Main portal vein tumor thrombus; Portal hypertension; Transjugular intrahepatic portosystemic shunt

Mesh:

Year:  2014        PMID: 24587637      PMCID: PMC3925870          DOI: 10.3748/wjg.v20.i6.1602

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  A new era for transjugular intrahepatic portosystemic shunts?

Authors:  Richard R Saxon
Journal:  J Vasc Interv Radiol       Date:  2004-03       Impact factor: 3.464

Review 2.  Management of HCC.

Authors:  Carlos Rodríguez de Lope; Silvia Tremosini; Alejandro Forner; María Reig; Jordi Bruix
Journal:  J Hepatol       Date:  2012       Impact factor: 25.083

3.  Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy.

Authors:  Michael J Wallace; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

4.  Early use of TIPS in patients with cirrhosis and variceal bleeding.

Authors:  Juan Carlos García-Pagán; Karel Caca; Christophe Bureau; Wim Laleman; Beate Appenrodt; Angelo Luca; Juan G Abraldes; Frederik Nevens; Jean Pierre Vinel; Joachim Mössner; Jaime Bosch
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

5.  The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients.

Authors:  J A Burger; A Ochs; K Wirth; D P Berger; R Mertelsmann; R Engelhardt; M Roessle; K Haag
Journal:  Ann Oncol       Date:  1997-02       Impact factor: 32.976

6.  Transjugular intrahepatic portosystemic shunts: experience in the oncology setting.

Authors:  Michael J Wallace; David C Madoff; Kamran Ahrar; Carla L Warneke
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

7.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.

Authors:  Christophe Bureau; Juan Carlos Garcia Pagan; Gilles Pomier Layrargues; Sophie Metivier; Pablo Bellot; Pierre Perreault; Philippe Otal; Juan-G Abraldes; Jean Marie Peron; Hervé Rousseau; Jaume Bosch; Jean Pierre Vinel
Journal:  Liver Int       Date:  2007-08       Impact factor: 5.828

8.  Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft.

Authors:  Klaus A Hausegger; Franz Karnel; Buriana Georgieva; Josef Tauss; Horst Portugaller; Hannes Deutschmann; Andrea Berghold
Journal:  J Vasc Interv Radiol       Date:  2004-03       Impact factor: 3.464

9.  Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years.

Authors:  Pieter C J ter Borg; Mirjam Hollemans; Henk R Van Buuren; Frank P Vleggaar; Michael Groeneweg; Wim C J Hop; Johan S Laméris
Journal:  Radiology       Date:  2004-03-24       Impact factor: 11.105

10.  Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesis.

Authors:  Xingshun Qi; Guohong Han; Chuangye He; Zhanxin Yin; Hongbo Zhang; Jianhong Wang; Jielai Xia; Hongwei Cai; Zhiping Yang; Ming Bai; Kaichun Wu; Daiming Fan
Journal:  Med Sci Monit       Date:  2012-08
View more
  6 in total

1.  Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.

Authors:  Lauren A Shreve; Cathal O'Leary; Timothy W I Clark; S William Stavropoulos; Michael C Soulen
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.

Authors:  Bin Qiu; Meng-Fei Zhao; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Fu-Liang He; Shan Dai; Jian-Nan Yao; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

3.  TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.

Authors:  Huzheng Yan; Zhenkang Qiu; Zhanwang Xiang; Mingsheng Huang; Fei Gao; Kai Feng
Journal:  Cancer Imaging       Date:  2022-02-19       Impact factor: 3.909

4.  TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension.

Authors:  Zhenkang Qiu; Guobao Wang; Huzheng Yan; Han Qi; Mengxuan Zuo; Guisong Wang; Weiwei Jiang; Zixiong Chen; Jingbing Xue; Ligong Lu; Fujun Zhang; Fei Gao
Journal:  Eur Radiol       Date:  2022-04-20       Impact factor: 7.034

5.  Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Ninggang Zheng; Xiaodong Wei; Dongzhi Zhang; Wenxiao Chai; Ming Che; Jiangye Wang; Binbin Du
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

6.  Clinical application of combined laparoscopic surgery in the treatment of primary hepatocellular carcinoma with portal hypertension: a report of 16 cases.

Authors:  Peng Guo; Shengtao Liao; Jianwei Li; Shuguo Zheng
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.